Graded Maximal Exercise Testing to Assess Mouse Cardio-Metabolic Phenotypes

Jennifer M. Petrosino1,7, Valerie J. Heiss1, Santosh K. Maurya2, Anuradha Kalyanasundaram3, Muthu Periasamy2, Richard A. LaFountain1, Jacob M. Wilson4, Orlando P. Simonetti5,6, Ouliana Ziouzenkova1*

1 Department of Human Sciences, The Ohio State University, College of Education & Human Ecology, Columbus, Ohio, United States of America, 2 Cardiovascular Pathobiology Program, Sanford Burnham Medical Research Institute at Lake Nona, Orlando, Florida, United States of America, 3 Department of Physiology and Cell Biology, The Ohio State University College of Medicine, Columbus, Ohio, United States of America, 4 Department of Human Performance, The University of Tampa, Tampa, Florida, United States of America, 5 Department of Radiology, The Ohio State University College of Medicine, Columbus, Ohio, United States of America, 6 Department of Cardiovascular Medicine, The Ohio State University College of Medicine, Columbus, Ohio, United States of America, 7 Biomedical Sciences Program, The Ohio State University, College of Medicine, Columbus, Ohio, United States of America

* ziouzenkova.1@osu.edu

Abstract

Functional assessments of cardiovascular fitness (CVF) are needed to establish animal models of dysfunction, test the effects of novel therapeutics, and establish the cardio-metabolic phenotype of mice. In humans, the graded maximal exercise test (GXT) is a standardized diagnostic for assessing CVF and mortality risk. These tests, which consist of concurrent staged increases in running speed and inclination, provide diagnostic cardio-metabolic parameters, such as, VO2max, anaerobic threshold, and metabolic crossover. Unlike the human-GXT, published mouse treadmill tests have set, not staged, increases in inclination as speed progresses until exhaustion (PXT). Additionally, they often lack multiple cardio-metabolic parameters. Here, we developed a mouse-GXT with the intent of improving mouse-exercise testing sensitivity and developing translatable parameters to assess CVF in healthy and dysfunctional mice. The mouse-GXT and PXTs were both tested in healthy mice (C57BL/6J, FVBN/J) to determine their ability to identify cardio-metabolic parameters (anaerobic threshold, VO2max, metabolic crossover) observed in human-GXTs. Next, these assays were tested on established diet-induced (obese-C57BL/6J) and genetic (cardiac isoform Casq2-/-) models of cardiovascular dysfunction. Results showed that both tests reported VO2max and provided reproducible data about performance. Only the mouse-GXT reproducibly identified anaerobic threshold, metabolic crossover, and detected impaired CVF in dysfunctional models. Our findings demonstrated that the mouse-GXT is a sensitive, non-invasive, and cost-effective method for assessing CVF in mice. This new test can be used as a functional assessment to determine the cardio-metabolic phenotype of various animal models or the effects of novel therapeutics.
Introduction

Obesity rates are rising exponentially and increase patients’ risks for developing cardiovascular diseases [1]. Heart disease remains the leading cause of death in the United States and worldwide. Subsequently, this has stimulated a large interest in understanding the metabolic and physiological mechanisms regulating cardiovascular function and energy balance. For over 50 years, human research has used graded maximal exercise testing (GXTt) as the prototypical method to study cardiovascular and metabolic responses of the body to stress [2–4]. These standardized GXTt tests, such as the gold standard Bruce protocol [5, 6], are key non-invasive and cost-effective methods for the assessing patient mortality risks [7, 8] and diagnosing coronary artery disease (CAD) [9].

New therapies for metabolic and cardiovascular disease have fast progressed with the development of genetic mouse models of cardiovascular dysfunction (reviewed in [10–14]). Genetic models, like the low-density lipoprotein receptor (Ldlr–/–) [11], apolipoprotein E (ApoE–/–) [15], and endothelial nitric oxide synthase (eNos3–/–) [16] knockout mice are well studied models of atherosclerosis. Similar to obese humans, diet-induced obese wild-type mice (WT-obese; C57BL/6J) can develop fatty streaks [17], left ventricular hypertrophy, and cardiac fibrosis [18–20]. Additionally, the WT-obese mouse model phenocopies the insulin resistant state, and subsequent impaired delivery of nutrients to skeletal muscles [21], that is seen in obese individuals during exercise testing [22]. Some knockout models are generated from mutations observed in patients with impaired cardiovascular function. These mouse models often phenotype human mutations, develop cardiac dysfunction, and can be used to generate highly translatable findings. For example, the calsequestrin 2 (cardiac specific isoform) deficit mouse (Casq2–/–) phenocopies humans with CASQ2 mutations. Both Casq2–/– mice and patients with CASQ2 mutations develop arrhythmias [23], catecholaminergic ventricular tachycardia, and can be diagnosed with exercise testing [24, 25]. Given the ability of mouse models to phenotype various aspects of cardiovascular disease, the use of mouse models has become critical to the study of cardiac biology, physiology, and novel therapeutics prior to translating findings to man [10, 12–14, 26].

As a result of the expanding number of mouse models used to study metabolic and cardiovascular disease, animal exercise testing has become widely published [27–54] as a way to functionally characterize the cardiovascular fitness (CVF) of mice [55–58]. Maximal exercise testing is designed to induce specific stress to working muscles and the heart. During testing, cardiac output primarily drives the associated increase in oxygen consumption (VO2) until maximal oxygen consumption (VO2max) and exhaustion is achieved. This resulting state of VO2max is characterized by sympathetic dominance, parasympathetic inhibition [59], and vasoconstriction to all systems but the heart, brain, and working muscles. While there are many conserved physiological responses between the cardiorespiratory systems of mice and men exposed to stress [60], there are also many differences that must be understood to enhance the interpretation and design of mouse exercise testing. The mouse heart is small (~0.2 g), beats between 400–600 beats per minute (bpm), and has a cardiac output (heart rate x strove volume) that is 2x-9x greater than humans. Differentially, the human heart is large (~250–300 g) and beats between 60–90 bpm at rest. Interestingly, when mouse and human stroke volume is normalized to bodyweight, there is not much discrepancy between the values recorded (reviewed in [13, 60, 61]). Many of the differences between human and mouse cardiac physiology are due to differences in heart size and rate, body mass, and oxygen requirements (reviewed in [60]). As a result, the information from exercise testing in mice and men will never be identical. Nonetheless, a lot of information can be generated from mouse treadmill
tests with calorimetry data reporting, so long as the following established GXT_h considerations are adapted to mouse testing protocols:

1. modest stage to stage increases in energy requirements
2. a testing duration greater than 6 minutes
3. a test lasting no longer than 12 minutes [2, 62] and
4. appropriate acclimation of animals to treadmills.

Without these considerations, tests may lack the appropriate intensity needed to accurately assess the CVF of mice.

Currently, exercise testing in mice and men diverge in the areas of test design, time of test, and parameters that can be reported. GXT_h tests have staged concurrent increases in speed and inclination over the course of 8–12 minutes [9]. However, unlike with human testing, there are no standardized protocols or end point criteria for positive tests in mice. Most rodent assays are designed with increasing speed over a fixed inclination (defined as PXT_m) for time periods greater than 12 minutes [23, 58, 63–69]. The most common variables reported in animal assays include VO2max, run time, and maximum run speed; which may not be sufficient for detection of impaired CVF [23]. Human testing differs in that it can derive additional diagnostic cardio-metabolic parameters such as anaerobic threshold (AT) [70], crossover (the shift from lipid to carbohydrate oxidation [71]), and pre- to post-test changes in lactate concentrations (Lactate-delta) [72]. These variables provide valuable information regarding the ability of the cardiac and pulmonary systems to deliver oxygen (O_2) during maximal and submaximal exercise intensities [73]. However, these parameters are rarely, if ever, reported in mouse testing because they cannot be accurately derived. Failure to derive these variables questions the ability of these assays to accurately assess mouse CVF. This, along with other limitations in currently utilized protocols (reviewed in [55, 74]), point out the need for a more efficacious and reliable standardized approach to test mouse CVF.

Here, we developed a new exercise testing method, the graded mouse maximal exercise test (GXT_m) and describe how to derive novel diagnostic cardio-metabolic parameters in mice that can be generated from data acquired during maximal exercise testing. Additionally, we compare a new GXT_m to a PXT_m and the human GXT_h. Our results showed that in mice, only the GXT_m was capable of generating cardio-metabolic parameters previously reported in human testing and consistently detecting impaired CVF in established mouse models of cardiovascular dysfunction.

**Methods**

**Human Studies**

**Study Approval.** For human testing, all subjects gave written informed consent prior to participation and all tests were done in accordance with procedures approved by The Ohio State University Biomedical Institution Review Board for this study. All animal experiments in this study were performed in accordance with procedures approved by Ohio State University Institutional Animal Care and Use Committee (IACUC) committee for this study and in accordance with the National Institutes of Health guidelines.

**Human Bruce protocol testing (GXT_h).** Healthy, recreationally trained men between 18 to 45 years of age were recruited from Columbus, Ohio to complete a Bruce protocol graded maximal treadmill exercise test following acclimation to test (n = 6). Testing was performed using ParvoMedics TrueOne 2400 systems and ParvoMedics software. ParvoMedics 2400 metabolic cart was turned on and allowed to warm up for at least thirty minutes prior to calibration.
and testing procedures. Pneumotachometer and gas analysis systems were calibrated according to manufacturer instructions before use during exercise testing. Expired gas was continuously sampled during exercise, through a 61 cm Nafton tube (Permapure, Toms River, NJ, USA), via paramagnetic oxygen analyzer (0–25% range with 0.1% accuracy) and an infrared carbon dioxide analyzer (0–10% range with 0.1% accuracy). Metabolic data was sampled using 15 seconds averaging. Testing stages consisted of simultaneous increases in speed and inclination as previously described [6] (Table 1). All human subjects were required to achieve at least three of the following criteria indicating VO$_2$max was reached: plateauing of oxygen consumption (VO$_2$), respiratory exchange ratio (RER) ≥ 1.1, heart rate ≥ 95% age-predicted maximal heart rate (APMHR), rating of perceived exertion (RPE) ≥ 17, respiratory rate (RR) > 40 breaths per minute, or subject inability to continue.

Animal Studies

**Animal subjects studied.** Mice were housed with 12-hour light and dark cycles and maintained on a standard chow diet. C57BL/6J (WT, n = 7), FVB/NJ (Jackson Laboratories, Bar

**Table 1. VO$_2$max testing protocols in mice and men.**

| Stage | Speed (meter/min) | Incline (% grade) | Duration (min) |
|-------|-------------------|-------------------|----------------|
| 1     | 6                 | 0                 | 5              |
| 2     | 7                 | 0                 | 0.5            |
| 3     | 8                 | 0                 | 0.5            |
| 4     | 9                 | 0                 | 0.5            |
| 5     | 10                | 0                 | 0.5            |
| 6     | 11                | 0                 | 1              |
| 7     | 12                | 0                 | 2              |
| 8     | 13                | 0                 | 2              |
| 9     | 14                | 0                 | 2              |
| 10    | 15                | 0                 | 2              |
| 11    | 16                | 0                 | 1              |

| Stage | Speed (km/hr) | Incline (% grade) | Duration (min) |
|-------|---------------|-------------------|----------------|
| 1     | 2.7           | 10                | 3              |
| 2     | 4             | 12                | 3              |
| 3     | 5.4           | 14                | 3              |
| 4     | 6.7           | 16                | 3              |
| 5     | 8             | 18                | 3              |
| 6     | 8.8           | 20                | 3              |
| 7     | 9.6           | 22                | 3              |

| Stage | Speed (meter/min) | Incline (% grade) | Duration (min) |
|-------|-------------------|-------------------|----------------|
| 1     | 9                 | 5                 | 2              |
| 2     | 12                | 10                | 2              |
| 3     | 15                | 15                | 2              |
| 4     | 18                | 15                | 1              |
| 5     | 21                | 15                | 1              |
| 6     | 23                | 15                | 1              |
| 7     | 24.0+             | 15                | 1              |

Stages, speed, and incline of maximal exercise tests completed are described.

doi:10.1371/journal.pone.0148010.t001
Harbor, Maine, \(n = 4\), obese C57BL/6J on high fat diet (45kcal/fat, Research Diets Inc, New Brunswick, NJ, ~100 days of high fat diet feeding, \(n = 11\)) and Calsequestrin 2 (cardiac isoform) null (Casp2\(^{-/-}\), \(n = 4\))(Mus musculus) \[23, 75\] male mice, 4–6 months old, were used. Metabolic and physiological parameters are described in S1 Table.

**Animal acclimatization to treadmills.** Animals were first acclimated (S2 Table) to the treadmill (Metabolic Modular Treadmill; Columbus Instruments, Columbus, OH, USA) and then rested for one week prior to performing the GXT\(_m\). Acclimation consisted of 3 training sessions with 60 hours recovery between sessions. During acclimation mice were placed in a motionless treadmill for 3 minutes, after which the shock grid was activated (3 Hz and 1.5 mA). Next, the treadmill was engaged to a walking speed of 6 m/min for 5 minutes and progressively increased up to 12 m/min for a total duration of 12 minutes of exercise.

**Software calibration and calculations from Metabolic Modulator Treadmill.** Before each testing session, Oxymax software (Columbus Instruments, Columbus, OH, USA) and open circuit indirect calorimetry treadmills (Metabolic Modular Treadmill, Columbus Instruments, Columbus, OH) \[76\] were calibrated and checked for hardware malfunctions according to manufacturer instructions. Prior to calibration, sample pump was turned on with flow indicator showing flow set at 4–5 LPM. Pressure reading was set at ~800mmHg and gas tank output pressure was set at 10psi. Gas calibration was performed and adjusted when necessary using the GAIN and FINE knobs to set reading at 0.50% CO\(_2\) and 20.5% O\(_2\). Drierite (Calcium Sulfate with Indicator, Sigma-Aldrich; St. Louis, MO, USA) was changed constantly to maintain accurate gas readings and to assure that moisture accumulating during testing could properly be absorbed. During testing, analysis was set to collect gas exchange measures every 15 seconds (settings: cage settle was set to every 15 sec; cage measure was set to every 15 sec; reference settle was set to every 30 sec; reference measure was set to every 30sec, volume rate unit was set to ml/kg/min, and accumulated gas unit was set as liter). During experiments, system sample pump maintained a constant sample flow reading of 0.5 L/min and sample drier a purge gas flow reading of 1.5 L/min. Maximum run speed (meter/min), shock grid contact (seconds) and time until exhaustion (min) were manually recorded with stopwatch. Oxymax computer software collected gas concentrations and flow to calculate oxygen consumption (VO\(_2\)), carbon dioxide expiration (VCO\(_2\)), and RER (VCO\(_2\)/VO\(_2\)) from the treadmill every 15 sec. Oxymax gas exchange calculations and generation of RER derived fuel substrate oxidation are additionally listed in the supplementary materials (S2 Text, S3 Table).

**Mouse Graded Maximal Exercise Test (GXT\(_m\)).** Following one week of rest from acclimation training, mice were placed on the treadmill at 0° incline and the shock grid was activated. The treadmill speeds were then increased until exhaustion as follows: (speed, duration, grade)—(0 m/min, 3 min, 0°), (6 m/min, 2 min, 0°), (9 m/min, 2 minutes, 5°), (12m/min, 2 min, 10°), (15m/min, 2 min, 15°) (18, 21, 23, 24 m/min, 1 min, 15°) and (+1 m/min, each 1 min thereafter, 15°). Exhaustion (endpoint for treadmill cessation) was defined as the point at which mice maintained continuous contact with the shock grid for 5 seconds. Continuous contact is defined as any portion of the animal’s body coming in contact with the shock grid for a total of 5 seconds. During the test, occasional (~1–5 times per single animal test) 1–2 second tail contacts were observed when animals misstepped or were slow to respond in the increase in intensity. VO\(_{2\text{max}}\) was determined by the peak oxygen consumption reached during this test when RER was >1.0. Maximum running speed was defined as the treadmill speed at which VO\(_{2\text{max}}\) was achieved (Table 1). All animals (within-subjects design, GXT\(_m\) and PXT\(_m\)) underwent pre- and post-test lactate assays (Lactate assay) one hour prior to and immediately following exercise testing.

**Mouse Progressive Maximal Exercise Test (PXT\(_m\)).** Following one week of rest after GXT\(_m\) the PXT\(_m\) was conducted as described in [56]. Specifically, mice were placed on the
treadmill (0° incline entire experiment) and the shock grid was activated. The treadmill speeds were then increased until exhaustion as follows: (speed, duration)—(0 m/min, 5 min), (6 m/min, 5 min), (7, 8, 9, and 10 m/min, 30s each), (11 m/min, 1 min), (12, 13, 14, and 15 m/min, 2 min each), and (+1 m/min, each 1 min thereafter). Exhaustion (endpoint for treadmill cessation) was defined as the point at which mice maintained continuous contact with the shock grid for 5 seconds (further described in the GXTm section). VO2 max was determined by the peak oxygen consumption reached during this test when RER was ≥ 1.0. Maximum running speed was defined as the treadmill speed at which VO2max was achieved. All animals (within-subjects design, GXTm and PXTm) underwent pre- and post-test lactate assays one hour prior to and immediately following exercise testing.

**Lactate assay.** A protocol [77] was adapted to measure venous blood lactate concentrations from the tail vein. During acclimation exercise sessions, mice were also acclimated to tail vein blood collection (3 pre acclimation session collections, and 3 post acclimation session collections). For the PXTm and GXTm; 1 hour prior to testing, ~0.7 μL of blood (via tail vein prick) was collected and placed for analysis on a handheld lactate meter (Lactate Plus; Nova Biomedical, Waltham, MA, USA). Within one minute of test completion, ~0.7 μL of blood was again collected and analyzed. For all testing, the same device was utilized to reduce variability.

**Statistical Analysis.** Data processing: Prior to analysis, the dependent variables with the four genotypes (WT, WT obese, Casq2−/−, FVB/NJ) and two test types (GXTm, PXTm) were examined through IBM SPSS version 22 (9.5.0.0) for accuracy of data entry, fit between their distributions, and the assumptions of multivariate analysis. Upon inspection of standardized scores, there were no univariate outliers. Mahalanobis distance values were requested and no multivariate outliers were identified as exceeding the Mahalanobis distance value at p < .01 (χ² = 32.00, df = 16, p = .01). Therefore, no additional cases were removed from the dataset. A review of plots of the residuals for each of the five dependent variables by group indicated that the assumption of independence was satisfied. Pairwise linearity was checked to determine the relationship between dependent variables using within-group scatterplots and also found to be satisfactory. All skewness and kurtosis statistics were between the range of -2 and 2, providing evidence that normality was a reasonable assumption. Further evidence of normality can be seen through the visible inspection of Q-Q plots and histograms of each dependent variable. There were no issues with normality observed.

Analyses and statistical tests: were performed with IBM SPSS Statistics 22 (9.5.0.0). All values represent mean SD unless noted otherwise. Two-Three group MANOVAS were performed. The Bonferroni correction when applied to an alpha of .05 yielded an alpha level of .007 for the univariate ANOVAs and Tukey HSD Multiple Comparisons presented. When appropriate, Student’s two-tailed t-test were applied with P-values <0.05 being considered significant. The results of the ANCOVA tests, with weight as a covariant, for the calorimetry data (VO2 data) and information regarding statistical test selection for calorimetry data analysis is further described in S3 Text.

## Results

**Development of a GXTm exercise assay for mice**

Our goal was to develop a test for mice that provided cardio-metabolic parameters previously reported in the human GXTh and to compare those parameters describing mouse performance during both the GXTm and PXTm. We used lean WT (C57BL/6J) male mice as a control group, C57BL/6j male mice with diet induced obesity (WT-Obese) as a non-transgenic model of cardiac deficiency [18–20, 78], and calsequestrin 2 (cardiac isoform) deficient (Casq2−/−) male mice as a genetic model with reported cardiac deficiency [23, 75] (S1 Table). During the study,
no animals experienced adverse effects from exercise testing that required them to be removed early from testing.

Within-subjects design for PXT\textsubscript{m} and GXT\textsubscript{m} was used to reduce errors associated with individual differences. Examples of representative single tests and the averaged measurements of all tests are shown in S1 and S2 Figs. Initially, we performed the GXT\textsubscript{m} and the PXT\textsubscript{m} using control WT male mice and the GXT\textsubscript{h} using healthy male human subjects. For all protocols, both mouse and human subjects underwent acclimation prior to testing. In mice, following the GXT\textsubscript{m}, an additional week of rest was given before animals performed the PXT\textsubscript{m}. This was done to minimize the effect of training induced adaptations. Of note, we performed the testing in opposite order and found no differences in performance (data not shown). Additionally, all mice underwent pre- and post-test lactate (LA) assays one hour prior to and following test termination (~within one minute of treadmill stopping and animal being removed) as biochemical confirmation that exhaustion was achieved.

We developed the GXT\textsubscript{m} protocol taking into consideration that most PXT\textsubscript{m} tests \cite{23, 58, 63–69, 79–83} increase the speed at a set incline over time (Table 1, Fig 1A) until maximal exertion and a respiratory exchange ratio (RER, the quotient of \(\frac{\text{VCO}_2}{\text{VO}_2}\)) \(\geq 1.0\) is achieved (S4 Table). VO\textsub{2max} testing is limited by the ability of the cardiorespiratory system to supply oxygen to working muscles. Experiments altering oxygen delivery (hypoxia), overperfusing muscles during exercise, and showing the contributions of cardiac output relative to arterial-venous oxygen (reviewed in \cite{84}) have been key in determining this concept. Accordingly, both the human and mouse GXT were designed to promote an end stage in which VO\textsub{2} fails to rise as oxygen demands increase. This end state is marked by predominately cardiac fatigue and an enhanced dependence on anaerobic glycolysis \cite{84} prior to the onset of skeletal muscle exhaustion.

In our human GXT\textsubscript{h} and established GXT\textsubscript{h} protocols (Table 1), there are simultaneous staged increases in speed and incline until the following conditions are met \cite{9}: 1) maximal exertion, 2) achievement of RER \(\geq 1.1\), 3) a plateau or decrease following peak oxygen consumption, 4) a significant increase in pre- to post-test venous blood LA concentrations (~8-10mmol/l), and 5) failure of heart rate to increase with increasing exercise intensity (S4 Table). We developed a similar, but not identical, GXT test in mice (GXT\textsubscript{m}) by have stages of simultaneous increases in speed and incline to achieve: 1) maximal exertion, 2) achievement of RER \(\geq 1.0\), 3) a plateau or decrease following peak oxygen consumption, and 4) a significant increase in post-test venous LA concentrations (~8mmol/l). Treadmill inclination increases, which were restricted to 5° increments, were capped at 15° due to observations in initial method development which showed that mice struggled to maintain natural gait with incline set >15°. The end points of all exercise tests are described in S5 Table. In mice, maximal exertion on the test was measured as time until exhaustion (minutes), and determined by ≥ 5 seconds of continuous contact with the shock grid. Continuous contact was defined as any portion of the animal’s body coming into contact with the shock grid. It should be noted that rarely were animals seen sitting down on the shock grid. Instead, most continuous contacts consisted of the animal’s tail or hind limb partially contacting the shock grid. Exhaustion was further validated using biochemical measures of circulating LA concentrations.

Reported measures in healthy mice and man during exercise testing

Oxygen consumption (VO\textsub{2}) and carbon dioxide expiration (VCO\textsub{2}) were two principal measures obtained from the metabolic treadmill (S1 and S2 Texts) during testing. In healthy WT mice, both the PXT\textsubscript{m} and GXT\textsubscript{m} showed increases in VO\textsub{2} and VCO\textsub{2} during testing (Fig 1B); however, in the majority of single PXT\textsubscript{m} tests, VCO\textsub{2} and VO\textsub{2} did not intersect at VO\textsub{2max}. This
suggested that true maximum was not achieved. In the GXTm, all single tests showed a clear intersection of VCO2 and VO2.

Time until exhaustion lasted for 20 to 29 minutes with PXTm excluding warm-up (Fig 1B). The most commonly used GXTh, the Bruce protocol, elicits time until exhaustion between 8–12 minutes in the general population [4, 5, 9]. Similarly to the reported data, our GXTh and GXTm tests achieved exhaustion between 8–12.5 minutes in WT mice and healthy humans (excluding warm-up) (Fig 1B). Furthermore, the GXTm data consistently produced VO2max values that were accompanied by exhaustive efforts and increased blood LA concentrations. Significant elevation of blood lactate post-test is a marker for the transition from aerobic to anaerobic metabolism and only consistently occurred in GXTm (data for all mouse groups are shown and discussed later).

RER was used to determine anaerobic threshold (AT) and fuel substrate (carbohydrate and lipid) oxidation (S3 Table) during testing. Anaerobic threshold (AT) is the point at which there is a shift from aerobic to anaerobic metabolism and signifies the onset of metabolic acidosis during continuous exercise [85]. The standard method for determining AT in humans is through multiple blood draws while running. This determination method was not feasible to execute in mice constrained in an enclosed metabolic treadmill. Thus, we determined AT using the method of identifying an abrupt increase in RER kinetics [85] and were able to consistently determine AT from RER kinetics in both human and mouse GXT single tests (Fig 2A).

AT was more difficult to consistently determine from single PXTm tests, and in those where it could be determined, it occurred approximately 20 minutes or longer into the test compared to the GXTm. Using RER values, we were also able to calculate a previously established GXTh parameter known as the crossover point (the transition from fat to carbohydrate oxidation [71]). Each single GXTm test and averaged test allowed for crossover determination (Fig 2B); however, a specific crossover point could not be determined from most single PXTm s (Fig 2B).
Crossover could be determined from the averaged PXTm (Fig 2B). In the averaged GXTm, compared to the averaged PXTm, crossover occurred sooner and at a similar time point to the GXTh (S1 Fig). Of note, cardio-metabolic parameters (VO2, VCO2, RER, AT, crossover) were derived from single tests, and then averaged, when completing analysis. Our findings indicated that longer tests with progressive intensity increases, like the PXTm, were not capable of producing VO2max with associated biochemical increases in lactate and parameters specific to an increased reliance on the glycolytic system (crossover, AT). These measures were; however, reported in both healthy mice and men during the GXTs.

Sensitivity of mouse testing methods to detect impaired cardiovascular fitness

Next, we quantitatively compared PXTm and GXTm tests in dysfunctional mouse models to assess their sensitivity in detecting impaired levels of CVF. Averaged kinetics for VO2 revealed differences among WT-lean, WT-obese, and Casq2-/− mice with the GXTm. With the PXTm, VO2 kinetics was similar between the Casq2-/− and obese mice; with both strains failing to show a progressive increase in VO2 over the course of the test (Fig 3A). Only the WT mice showed increases in VO2 as the PXTm progressed. With the PXTm, relative VO2max (VO2max normalized to body weight) was only significantly suppressed in the obese group. Additionally, VO2max was unchanged between the WT and the Casq2-/− (Fig 3B). With the GXTm, relative VO2max was significantly suppressed in both dysfunctional models (alpha = .007, MANOVA, Tukey HSD Multiple Comparisons; p < .001, WT v. obese; p = .001; WT v. Casq2-/−; p = .001 obese v. Casq2-/−; Fig 3B). Of note, an expected increase from basal VO2 to VO2max (VO2delta) was achieved in all tests (PXTm, GXTm) with the exception of WT v. obese using the PXTm (alpha = .007, MANOVA, Tukey HSD Multiple Comparisons; p = .006, WT v. obese; Fig 3C). However, this could have been observed as a result of the PXTm eliciting a smaller VO2delta in WT compared to the GXTm (p < .05, Student’s t-Test). We validated all data with an additional control strain (S5 and S7 Tables) to further confirm the sensitivity of each test.
Similar to VO2max data, only the GXTm provided a significant decrease in time until exhaustion in the Casq2−/− and obese mice (alpha = .007; MANOVA, Tukey HSD Multiple Comparisons; p = .006, Casq2−/−; p = .001, obese; Fig 4A). Maximum run speed was also only significantly reduced with the GXTm, but not the PXTm, in both dysfunctional models (alpha = .007; MANOVA, Tukey HSD Multiple Comparisons; p = .006, Casq2−/−; p = .001, obese; Fig 5C). In the PXTm, significant reductions in time until exhaustion and run speed were not observed in the dysfunctional groups (Fig 4A and Fig 5C). This indicated that the PXTm did not induce sufficient cardiovascular stress to allow for the detection of impaired CVF in established models of cardiac insufficiency. The results of the ANCOVA tests with weight being used as a covariant for the calorimetry data (VO2 and other variables) are also described and discussed in S3 Text.

Fig 3. VO2max achieved with the GXTm, but not the PXTm, identifies impaired cardiovascular fitness in mouse models of cardiovascular dysfunction. (A) Averaged VO2 kinetics obtained from WT (dashed line), Casq2−/− (solid thick line), and obese (solid line) mice that performed the PXTm and GXTm. VO2 is indicated for each group from the beginning of the test until the end (Minute 2, after the 2 minute warm, to point of exhaustion). Of note, during the PXTm, the largest increase in VO2 occurred with the first stage, and leveled off as the test continued in dysfunctional models. (B) Relative VO2max values and (C) change from baseline to maximal oxygen consumption (VO2max) are compared (mean±SD, MANOVA, Tukey HSD Multiple Comparisons, alpha = .007) in WT-healthy (white bar), WT-obese (hashed bar), and Casq2−/− (black bar) mice. Asterisks indicate significance at the alpha = .007 level (MANOVA, multiple comparisons Tukey HSD for the PXTm and GXTm of WT v. obese and WT v. Casq2−/−), hash indicates significant difference at the alpha = .05 level between tests for the same genotypes (Student’s t-Test), and diamond indicates significance at the alpha = .007 level (MANOVA, multiple comparisons Tukey HSD for the PXTm and GXTm of obese v. Casq2−/−).

doi:10.1371/journal.pone.0148010.g003

Development of a Mouse Graded Exercise Test
exercise with ECG monitoring have shown that Casq2-/- mice display cardiovascular dysfunction in the form of catecholaminergic polymorphic ventricular tachycardia [23]. The onset of exhaustion is validated in human testing by elevated post-test blood LA (LA delta; LA_post - LA_pre) concentrations (~8-10mmol/L) compared to baseline [4, 55, 74]. We observed significant increases in LA delta using the GXTm compared to the PXTm in WT and Casq2-/- groups. With the GXTm, Casq2-/- mice had significantly greater LA delta compared to WT; however, with the PXTm, this parameter was decreased compared to controls (Fig 4B, S9 Table). In humans with myocardial ischemia, a hallmark response to a GXTh is a significant increase in circulating blood LA concentrations compared to healthy subjects [89]. Thus, this response was replicated with the GXTm in the genetic model of cardiac insufficiency (9.32 ±1.53mmol/L, Casq2-/- v. 6.63 ±1.7mmol/L; WT; Student’s t-Test, alpha = .05; Fig 4B, S9 Table).

RER kinetics indicated that PXTm could not clearly determine AT to assess CVF; however, RER kinetics from all single GXTm was capable of determining AT in healthy and dysfunctional models. No significant difference was found between the mean relative AT in functional and dysfunctional mice using the PXTm (alpha = .007, MANOVA, Tukey HSD Multiple Comparisons, p = .002; WT v. Casq2-/- during GXTm; Fig 5B). With the GXTm, Casq2-/- mice also had significantly higher relative ATs compared to WT controls. Thus, with GXTm, AT was lower in dysfunctional mice; a finding similar to those from human research looking at AT in patients with cardiac disease above functional class I (S5 Text, [90]). Together, these results demonstrated that the GXTm, like the GXTh, was able to simultaneously elicit exhaustive efforts, true VO2max, and shift to anaerobic metabolism [4, 72, 74, 89, 91].

Fuel utilization differs between healthy mice and models of cardiovascular dysfunction during exercise testing

We determined values of carbohydrate or fat oxidation during both the PXTm and GXTm by converting RER values recording during testing into their respective fat and carbohydrate oxidation values (Fig 6, S3 Table).
With PXT<sub>m</sub> there were multiple crossover points from fat to carbohydrate oxidation during tests, making it difficult to identify a single crossover point. Unlike the PXT<sub>m</sub>, the GXT<sub>m</sub> allowed for identification of an accurate crossover point in all single tests. In humans, crossover

Fig 5. Anaerobic threshold and maximum speed assess dysfunction in mice with the GXT<sub>m</sub>, but not the PXT<sub>m</sub>. (A) Average RER kinetics from same from WT (dashed line), Casq2<sup>−/−</sup> (solid thick line), and obese (solid line) mice performed the PXT<sub>m</sub> and GXT<sub>m</sub>. (B) AT was reported as %AT, a time point where AT occurred/total test time in mouse groups (Fig 3). (C) Maximum speed achieved on test (m/m). For all measures, asterisks indicates significance at the alpha = .007 level (MANOVA, multiple comparisons Tukey HSD for the PXT<sub>m</sub> and GXT<sub>m</sub> of WT v. obese and WT v. Casq2<sup>−/−</sup>). hash indicates significant difference at the alpha = .05 level between tests for the same genotype (Student’s t-Test), and diamond indicates significance at the alpha = .007 level (mean ± SD, MANOVA, multiple comparisons Tukey HSD for the PXT<sub>m</sub> and GXT<sub>m</sub> of obese v. Casq2<sup>−/−</sup>).

doi:10.1371/journal.pone.0148010.g005

Fig 6. Carbohydrate and fat oxidation kinetics can be used to identify the crossover point in the GXT<sub>m</sub>, but not the PXT<sub>m</sub>. Averaged fuel utilization kinetics in WT (n = 7), obese (n = 11), and Casq2<sup>−/−</sup> (n = 4) mice. Fat (dashed line) and carbohydrate (Carb, solid line) oxidation were derived from RER as described in S3 Table during the PXT<sub>m</sub> (A) and GXT<sub>m</sub> tests (B). In GXT<sub>m</sub> tests, the arrow indicates crossover, the point at which carbohydrate and fat oxidation intersect (dashed arrows).

doi:10.1371/journal.pone.0148010.g006
occurs at between 60–80% of aerobic power [71]. We observed crossover in this range with all genotypes on the GXTm. Specifically, it occurred sooner in the Casq2−/− compared to WT controls (Student’s T-test, p < .05; WT v. Casq2−/−; Fig 7A). Time to 100% carbohydrate oxidation during GXTm testing was significantly shorter in dysfunctional animals compared to WT mice (Student’s T-test, p < .05; WT v. Casq2−/−, p < .05; WT v. obese; Fig 7B) and the rate of carbohydrate oxidation after crossover was decreased (Student’s T-test, p < .05; WT v. Casq2−/−, p < .05; WT v. obese; Fig 7C). Together these results indicated that substrate utilization parameters from the GXTm could be used to identify the crossover point and determine fuel use during aerobic and anaerobic stress conditions.

**Discussion**

**GXT design considerations**

For over 50 years, exercise testing has served as an established and validated method for diagnostic and prognostic assessment of CVF in the clinical setting [9]. Physicians and exercise physiologists value the use of the GXTs for induction of physiological stress [92] to the cardiopulmonary system in a controlled environment with simultaneous monitoring of myocardial oxygen demands [93], biochemical [94], and metabolic [71] responses. Furthermore, it is a validated method of evaluating the status of patients with cardiovascular and pulmonary disease [2]. Established GXTs tests involve gradual increases in work output over multi-stage increases in speed and inclination [95] (Table 1). When generating the GXTm, we applied the same principle design and used staged increases in speed and inclination, as well as similar end point criteria for a positive test (S4 Table). Since both human and mouse exercise tests analyze VCO2, VO2, and RER through the use of indirect calorimetry; an attempt was made to utilize information generated from metabolic data while acknowledging the differences which will always persist between species.

**Fig 7.** Carbohydrate and fat oxidation parameters from the GXTm, but not the PXTm, can be used to identify impaired cardiovascular fitness in dysfunctional models. (A) Fuel utilization kinetics (Fig 6B) from the GXTm were used to quantify the percent of the test at which the crossover point was achieved relative to total time of test (% of test time at which crossover is achieved is the minute crossover occurred divided by total test time and multiplied by 100). Asterisk indicates significance at the alpha = .007 level (MANOVA, multiple comparisons Tukey HSD for the GXTm). (B) Time until 100% carbohydrate oxidation. Asterisks show significant difference between dysfunctional v. WT groups, (Student’s T-test, GXTm for WT v. obese and WT v. Casq2−/−). (C) Rate of carbohydrate oxidation after crossover in all mouse groups. This rate is determined by dividing time after crossover by total time of test (100%) (Student’s T-test for the GXTm for WT v. obese and WT v. Casq2−/−). Bar graphs represent mean ± SD.

doi:10.1371/journal.pone.0148010.g007
The available equipment for exercise test in mice and human is another factor that was considered during development of the GXT<sub>m</sub>. In human tests, VCO<sub>2</sub> and VO<sub>2</sub> are measured each breath, whereas with mice, this information is generated from the gas exchange occurring inside the metabolic chamber which encloses the treadmill mice run on. Without the ability to calculate single breath values in running mice, the ventilatory rate cannot be calculated. Furthermore, the diffusion of gas from the chamber to the sensor elicits an approximate one-minute lag in mice testing. Thus, this must be accounted for data interpretation and analysis. Given that some of the biggest differences between mouse and human cardiac physiology occur in respect to heart rate, size, and oxygen requirements (reviewed in [60]), we recognized it was essential to rely on variables which were normalized to animal size and oxygen rates (RER, fuel substrate oxidation) to focus the similarities of comparative exercise physiology of mice and men.

Another difference between human and mouse testing included test termination. A shock grid wills maximal exertion attempts in mice; whereas in humans, they run at their own volition. Accordingly, appropriate acclimation to treadmill testing must be completed in mice to reduce the physiological and psychological stress potentially associated with their initial introduction to shock. Outside of these limitations though, the adjustments we made to stage length and intensity, and the alterations we made to account for perpetual differences between mice and humans, allowed us to develop a method of exercise testing for mice that induced true VO<sub>2max</sub> and generated a set of variables that were comparable to data acquired from human testing (AT, crossover, Lactate<sub>delta</sub>).

### Development of a Mouse Graded Exercise Test

The field of exercise physiology has established that the relationship between VO<sub>2</sub> and work rate diminishes in tests lasting less than 6 minutes or greater than 12 minutes [2]. Furthermore, they have shown that tests lasting over 12 minutes provide data that is impacted by skeletal muscle fatigue and orthopedic issues [2]. The PXT<sub>m</sub> was composed of a large volume of submaximal work. During this exercise intensity, there is a decreased demand for oxygen and a reduction in the redistribution of blood from inactive to active tissues. This submaximal intensity delays time until maximum cardiac output, ventilation, and VO<sub>2max</sub> [63]. In the PXT<sub>m</sub>, this type of scenario occurs, as the cardiovascular system is not maximally stressed until later stages of the test. Accordingly, this test can be considered too long to specifically stress the cardiorespiratory system and its ability to withstand metabolic stress. Our data showed that the PXT<sub>m</sub> is likely a superior test for assessing aerobic exercise capacity and aerobic endurance; whereas, the GXT<sub>m</sub> is superior for assessing CVF.

A long test can be problematic if a researcher wants to report parameters beyond maximum run speed or duration, such as AT and crossover, to determine the cardiometabolic phenotype of a mouse. This limitation was observed in classic PXT<sub>m</sub>, as it was incapable of producing RER kinetics to determine AT. Typically AT can be identified by a nonlinear increase in minute ventilation [92]; however, this is not feasible for most researchers to calculate in mouse models during exercise [96]. In our GXT<sub>m</sub> test we were able to use abrupt exponential increases in RER to determine the point at which AT occurred in both WT and dysfunctional models. These AT values derived in our GXT<sub>m</sub> provided a sensitive measure for determining CVF in mice. Clinically, AT has been used in patients with cardiorespiratory disease to assess exercise tolerance [85]; however, the ability to derive AT from an exercise test has additional applications such as evaluating endurance performance, exercise prescription, and determining the effects of drugs on exercise tolerance (reviewed in [97]). Thus, the ability of the GXT<sub>m</sub> to derive AT values highlighted its capability to generate novel noninvasive diagnostics and quantitative assessments of CVF in various mouse models.
Metabolic crossover, an old human metabolic parameter with new applications in mouse testing

We found the GXT\textsubscript{m} was capable of predicting AT based off of RER values, but it was also capable of determining the specific point of crossover from predominate lipid to carbohydrate oxidation during testing. This shift in fuel substrate utilization, known as the crossover concept [98], demonstrates that as relative VO\textsubscript{2} and power output increase, there is a shift to predominate carbohydrate utilization. Thus, the shift from predominant of lipid oxidation to an increased dependence on muscle glycogen and blood glucose substrates [98] is intensity driven. This concept had been well established with methods such as radio-tracers, tissue metabolite sampling, stable isotopes, and indirect calorimetry in mammals and man [99] (reviewed in [98]). With the GXT\textsubscript{m}, the use of glycogen and glucose oxidation increased exponentially with exercise intensity and, therefore, allowed for crossover determination (Figs 6 and 7). It should be noted, as demonstrated in the data of a single WT mouse (Fig 2), that AT and crossover did not occur simultaneously in the GXT\textsubscript{m} testing and were both difficult to interpret in PXT\textsubscript{m} testing. The effect seen in the GXT\textsubscript{m} could potentially be due to pyruvate dehydrogenase (PDH) mediated LA accumulation and aerobic substrate oxidation [100]. In working muscles, transformation of the pyruvate dehydrogenase complex (PDHc) to the active form (PDHa) is complete at approximately 80\% VO\textsubscript{2}\textsubscript{max} [101]; however, crossover occurs at approximately 65\% percent of VO\textsubscript{2}\textsubscript{max} [71]. With the GXT\textsubscript{m}, both crossover and AT were found around these approximations, with crossover occurring at 62–75\% and AT occurring between 68–87\% in mice. Regardless of these differences, the crossover obtained in our study with established model cardiovascular dysfunction was similar; yet significantly different than the healthy WT controls.

Standardized methods for the functional assessment of cardiovascular fitness in mice

Without a gold standard \textit{in vivo} exercise assay, reported data become both unreliable and difficult to reproduce between researchers. Previous mouse exercise assays have not considered both components of human exercise testing and the limitations of exercise testing in mice. However, as we have shown, certain testing conditions in mice allow for the reporting of cardio-metabolic parameters previously only reported in human testing. With the appropriate considerations to test design and differences between mouse and human physiology, tests like the GXT\textsubscript{m} can serve as noninvasive, cost effective, methods to assess the cardio-metabolic phenotype of mice. Our data showed that the GXT\textsubscript{m} was able to consistently provide data about the CVF of various models, and thus, could be used in the future to examine the effects of various treatments and therapeutics.

Alternative cardiac challenges using echocardiography [102] and cardiac magnetic resonance imaging (cMRI) [103] are popularized protocols to stress and test the cardiovascular system in mouse models; however, they are expensive and require animals to be anesthetized. Anesthesia prevents animal heart rates from achieving the true physiological responses to reagents and compromises cardiac output, a measure of blood being pumped by the heart per minute. Unlike these procedures, exercise assays have been shown to elicit a 2-fold increase in cardiac output [104] while avoiding limitations of anesthesia. Appropriate exercise testing and exercise prescription clearly have a place in the assessment and management of cardiovascular disease. Accordingly, exercise testing and prescription could carry a similar weight in mouse cardiovascular research if there was more standardization amongs the methods used to determine CVF in mice. If research done on mice is aimed at elucidating mechanisms of disease and therapies; then it is critical to apply tests that specifically test the CVF of mice when assessing cardio-metabolic function.
Supporting Information

S1 File. Contains supporting tables, figures, and notes.

(DOCX)

Acknowledgments

We thank Dr. Alexander Lucas, Dr. Brian Focht, Grant Foglesong, and Shawn Flanagan their suggestions during manuscript generation.

Author Contributions

Conceived and designed the experiments: JMP RAL OPS. Performed the experiments: JMP RAL OPS. Analyzed the data: JMP VJH. Contributed reagents/materials/analysis tools: AK SKM MP JMW. Wrote the paper: JMP OZ.

References

1. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006; 113(8):898–918. doi: 10.1161/CIRCULATIONAHA.106.171016 PMID: 16380542.

2. Balady GJ, Arena R, Sietsema K, Myers J, Coke L, Fletcher GF, et al. Clinician’s Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circulation. 2010; 122(2):191–225. Epub 2010/06/30. doi: 10.1161/CIR.0b013e3181e52e69 PMID: 20585013.

3. Ehrman JK, American College of Sports Medicine. ACSM’s resource manual for Guidelines for exercise testing and prescription. 6th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2010. xxiv, 868 p.

4. Pescatello LS, American College of Sports Medicine. ACSM’s guidelines for exercise testing and prescription. 9th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health; 2014. xxiv, 456 p.

5. Bruce RA, Kusumi F, Hosmer D. Maximal oxygen intake and nomographic assessment of functional aerobic impairment in cardiovascular disease. American heart journal. 1973; 85(4):546–62. PMID: 4632004.

6. Mead WF. Maximal exercise testing—Bruce protocol. The Journal of family practice. 1979; 9(3):479–90. PMID: 479779.

7. Kodama S, Saito K, Tanaka S, Makii M, Yachi Y, Asumi M, et al. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. JAMA: the journal of the American Medical Association. 2009; 301(19):2024–35. doi: 10.1001/jama.2009.681 PMID: 19454641.

8. Gupta S, Rohatgi A, Ayers CR, Willis BL, Haskell WL, Khera A, et al. Cardiorespiratory fitness and classification of risk of cardiovascular disease mortality. Circulation. 2011; 123(13):1377–83. doi: 10.1161/CIRCULATIONAHA.110.003236 PMID: 21422392; PubMed Central PMCID: PMC3926656.

9. Swain DP, American College of Sports Medicine, American College of Sports Medicine. ACSM’s resource manual for guidelines for exercise testing and prescription. 7th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2014. xv, 862 p.

10. Chu G, Haghighi K, Kranias EG. From mouse to man: understanding heart failure through genetically altered mouse models. Journal of cardiac failure. 2002; 8(Suppl):S432–49. doi: 10.1054/jcaf.2002.129284 PMID: 12555156.

11. Jawien J, Nastalek P, Korbout R. Mouse models of experimental atherosclerosis. Journal of physiology and pharmacology: an official journal of the Polish Physiological Society. 2004; 55(3):503–17. PMID: 15381823.

12. Russell LK, Finck BN, Kelly DP. Mouse models of mitochondrial dysfunction and heart failure. Journal of molecular and cellular cardiology. 2005; 38(1):81–91. doi: 10.1016/j.yjmcc.2004.10.010 PMID: 15623424.

13. Breckenridge R. Heart failure and mouse models. Disease models & mechanisms. 2010; 3(3–4):138–43. doi: 10.1242/dmm.005017 PMID: 20212081.

14. Fiedler LR, Mafoszie E, Schneider MD. Mouse models of heart failure: cell signaling and cell survival. Current topics in developmental biology. 2014; 109:171–247. doi: 10.1016/B978-0-12-397920-9.00002-0 PMID: 24947238.

15. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proceedings of the National Academy of Sciences U S A. 2001; 98(19):10658–63. doi: 10.1073/pnas.191263498 PMID: 11536072.
of Sciences of the United States of America. 1992; 89(10):4471–5. PMID: 1584779; PubMed Central PMCID: PMC49104.

16. Shesely EG, Maeda N, Kim HS, Desai KM, Kregel JH, Laubach VE, et al. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proceedings of the National Academy of Sciences of the United States of America. 1996; 93(23):13176–81. PMID: 8917564; PubMed Central PMCID: PMC24066.

17. Li Y, Gilbert TR, Matsumoto AH, Shi W. Effect of aging on fatty streak formation in a diet-induced mouse model of atherosclerosis. Journal of vascular research. 2008; 45(3):205–10. doi: 10.1159/000112133 PMID: 1806366; PubMed Central PMCID: PMC2373261.

18. Aoyagi T, Higa JK, Aoyagi H, Yorichika N, Shimada BK, Matsui T. Cardiac mTORC1 rescue the detrimental effects of diet-induced obesity in the heart after ischemia-reperfusion. American journal of physiology Heart and circulatory physiology. 2015; 308(12):H1530–9. doi: 10.1152/ajpheart.00008.2015 PMID: 25888508; PubMed Central PMCID: PMC4469881.

19. Winzell MS, Ahren B. The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerence and type 2 diabetes. Diabetes. 2004; 53 Suppl 3:S215–9. PMID: 15561913.

20. Zeng H, Vaka VR, He X, Booz GW, Chen JX. High-fat diet induces cardiac remodeling and dysfunction: assessment of the role played by SIRT3 loss. Journal of cellular and molecular medicine. 2015. doi: 10.1111/jcmm.12556 PMID: 25782072.

21. Kubota T, Kubota N, Kumagai H, Yamaguchi S, Kozono H, Takahashi T, et al. Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell metabolism. 2011; 13(3):294–307. doi: 10.1016/j.cmet.2011.01.018 PMID: 21356519.

22. Barrett EJ, Eggleston EM, Inyard AC, Wang H, Li G, Chai W, et al. The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action. Diabetologia. 2009; 52(5):752–64. doi: 10.1007/s00125-009-1313-z PMID: 19283361; PubMed Central PMCID: PMC2704146.

23. Knollmann BC, Chopra N, Hlaing T, Akin B, Yang T, Ettensohn K, et al. Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia. The Journal of clinical investigation. 2006; 116(9):2510–20. Epub 2006/08/26. doi: 10.1172/JCI29128 PMID: 16932808; PubMed Central PMCID: PMC1551934.

24. Francis J, Sankar V, Nair VK, Priori SG. Catecholaminergic polymorphic ventricular tachycardia. Heart rhythm: the official journal of the Heart Rhythm Society. 2005; 2(5):550–5. doi: 10.1542/arr.2005-0072 PMID: 15840485.

25. Postma AV, Denjoy I, Hoorntje TM, Lupoglazoff JM, Da Costa A, Sebillon P, et al. Absence of calsequestrin alters the gut microbiome in C57BL/6J mice. Journal of applied physiology. 2015: Epub 2014/11/03. doi:10.1152/ajp Physiol.2014.00025.2014 PMID: 25691103.

26. Abdurrachim D, Luiken JJ, Nicolay K, Glatz JF, Prompers JJ, Nabben M. Good and bad consequences of hyperglycemia in murine skeletal muscle lacking synemin. American journal of physiology Cell physiology. 2015; 308(6):6451–60. doi: 10.1152/ajpcell.00008.2015 PMID: 25888508; PubMed Central PMCID: PMC4469881.

27. Aoi W, Ogaya Y, Takami M, Konishi T, Sauchi Y, Park EY, et al. Glutathione supplementation suppresses cardiac mSin3A accumulation and improves cardiac function in a rat model of type 2 diabetes. The Journal of cellular and molecular medicine. 2015. doi: 10.1111/jcmm.12556 PMID: 25782072.

28. Fentz J, Kjobsted R, Birk JB, Jordy AB, Jeppesen J, Thorsen K, et al. AMPKalpha is critical for enhancing glucose and fatty acid metabolism in heart failure: Evidence from mouse models. Cardiovascular research. 2015. doi: 10.1093/crv/cvx105 PMID: 25765396.

29. Aschar-Sobbi R, Izaddoustdar F, Korogyi AS, Wang Q, Farman GP, Yang F, et al. Increased atrial arrhythmia susceptibility induced by intense endurance exercise in mice requires TNFalpha. Nature communications. 2015; 6:6018. Epub 2015/02/20. doi:10.1038/ncomms7018 PMID: 25598495.

30. Cho J, Shin MK, Kim D, Lee I, Kim S, Kang H. Treadmill Running Reverses Cognitive Declines due to Alzheimer's Disease. Medicine and science in sports and exercise. 2015. Epub 2015/01/13. doi:10.1249/mss.0000000000000612 PMID: 2574797.

31. Borsting Jordy A, Kraakman MJ, Gardner T, Estevez E, Kammoun HL, Wein J, et al. Analysis of the liver lipidome reveals insights into the protective effect of exercise on high fat diet induced hepatosteatosis in mice. American journal of physiology Endocrinology and metabolism. 2015. Epub 2015/02/26. doi: 10.1152/ajpendo.00547.2014 PMID: 25714675.

32. Fentz J, Kjobsted R, Birk JB, Jordy AB, Jeppesen J, Thorsen K, et al. AMPKalpha is critical for enhancing skeletal muscle fatty acid utilization during in vivo exercise in mice. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2015. Epub 2015/01/23. doi: 10.1096/fj.14-266650 PMID: 25600422.

33. Garcia-Pelagio KP, Muriel J, O’Neill A, Desmond PF, Lovering RM, Lund L, et al. Myopathic changes in murine skeletal muscle lacking synemin. American journal of physiology Cell physiology. 2015; 308(6):6451–60.

34. Development of a Mouse Graded Exercise Test
Development of a Mouse Graded Exercise Test

C44–62. Epub 2015/01/09. doi: 10.1152/ajpcell.00331.2014 PMID: 25567810; PubMed Central PMCID: PMCPmc4360028.

35. Giacomello E, Quarta M, Paolini C, Squecco R, Fusco P, Toniolo L, et al. Deletion of small ankyrin 1 (sAnk1) isoforms results in structural and functional alterations in aging skeletal muscle fibers. American journal of physiology Cell physiology. 2015; 308(2):C123–38. Epub 2014/10/31. doi: 10.1152/ajpcell.00090.2014 PMID: 25354526.

36. Kadoguchi T, Kinugawa S, Takada S, Fukushima A, Furhata T, Homma T, et al. Angiotensin II can directly induce mitochondrial dysfunction, decrease oxidative fibre number and induce atrophy in mouse hindlimb skeletal muscle. Experimental physiology. 2015; 100(3):312–22. Epub 2015/01/13. doi: 10.1113/expphysiol.2014.084095 PMID: 25580531.

37. Kim DS, Cha HN, Jo HJ, Song IH, Baek SH, Dan JM, et al. TLR2 deficiency attenuates skeletal muscle atrophy in mice. Biochemical and biophysical research communications. 2015. Epub 2015/03/10. doi: 10.1016/j.bbrc.2015.02.144 PMID: 25749338.

38. Knudsen JG, Biensø RS, Hassing HA, Jakobsen AH, Pilegaard H. Exercise-induced regulation of key factors in substrate choice and gluconeogenesis in mouse liver. Molecular and cellular biochemistry. 2015. Epub 2015/02/24. doi: 10.1007/s11010-015-2351-0 PMID: 25702176.

39. Lin TW, Shih YH, Chen SJ, Lien CH, Chang CY, Huang TY, et al. Running exercise delays neurodegeneration in amygdala and hippocampus of Alzheimer’s disease (APP/PS1) transgenic mice. Neurobiology of learning and memory. 2015; 118:189–97. Epub 2014/12/30. doi: 10.1016/j.nlm.2014.12.005 PMID: 25543023.

40. MacPherson RE, Huber JS, Frendo-Cumbo S, Simpson JA, Wright DC. Adipose Tissue Insulin Action and IL-6 Signaling following Exercise in Obese Mice. Medicine and science in sports and exercise. 2015. doi: 10.1249/mss.0000000000000660 PMID: 25785928.

41. Marchon C, de Marco Omelais E, da Silva Viegas KA, Lacchini S, de Souza RR, Fonseca FL, et al. Effects of moderate exercise on the biochemical, physiological, morphological and functional parameters of the aorta in the presence of estrogen deprivation and dyslipidemia: an experimental model. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology. 2015; 35(1):397–405. Epub 2015/01/17. doi: 10.1159/000369705 PMID: 25591780.

42. Pate KM, Sherk VD, Carpenter RD, Weaver M, Crapo S, Gally F, et al. The beneficial effects of exercise on cartilage are lost in mice with reduced levels of ECSOD in tissues. Journal of applied physiology. 2015; 118(6):760–7. Epub 2015/01/17. doi: 10.1152/japplphysiol.00112.2014 PMID: 25593283.

43. Piguet AC, Saran U, Simillion C, Keller I, Terracciano L, Reeves HL, et al. Regular exercise decreases liver tumors development in hepatocyte-specific PTEN-deficient mice independently of steatosis. Journal of physiology. 2015; 593(1):331–405. Epub 2014/12/19. doi: 10.1113/jphysiol.2014.282640 PMID: 25556804; PubMed Central PMCID: PMCPmc4293071.

44. Pincu Y, Linden MA, Zou K, Baynard T, Boppart MD. The effects of high fat diet and moderate exercise on tumors development in hepatocyte-specific PTEN-deficient mice independently of steatosis. Journal of physiology. 2015; 593(1):331–405. Epub 2014/12/19. doi: 10.1113/jphysiol.2014.282640 PMID: 25556804; PubMed Central PMCID: PMCPmc4293071.

45. Pincu Y, Linden MA, Zou K, Baynard T, Boppart MD. The effects of high fat diet and moderate exercise on tumors development in hepatocyte-specific PTEN-deficient mice independently of steatosis. Journal of physiology. 2015; 593(1):331–405. Epub 2014/12/19. doi: 10.1113/jphysiol.2014.282640 PMID: 25556804; PubMed Central PMCID: PMCPmc4293071.

46. Sashindranath M, Daglas M, Medcalf RL. Evaluation of gait impairment in mice subjected to craniotomy and traumatic brain injury. Behavioural brain research. 2015; 286:33–8. Epub 2015/02/18. doi: 10.1016/j.bbr.2015.02.038 PMID: 25721743.

47. Sommer W, Knofel AK, Izykowski N, Oldhafer F, Aysar M, Jonigk D, et al. Physical exercise reduces transplant arteriosclerosis in a mouse aorta transplantation model. The Journal of thoracic and cardiovascular surgery. 2015; 149(1):330–7. Epub 2014/12/20. doi: 10.1016/j.jtcvs.2014.10.029 PMID: 25524887.

48. Uchiyama M, Jin X, Yin E, Shimokawa T, Niimi M. Treadmill exercise induces murine cardiac allograft survival and generates regulatory T cell. Transplant international: official journal of the European Society for Organ Transplantation. 2015; 28(3):352–62. Epub 2014/11/20. doi: 10.1111/tri.12491 PMID: 25406375.

49. Vogel J, Kruse C, Zhang M, Schroder K. Nox4 supports proper capillary growth in exercise and retina neovascularization. The Journal of physiology. 2015. Epub 2015/02/06. doi: 10.1113/jphysiol.2014.284901 PMID: 25652847.

50. Wallace IJ, Gupta S, Sankaran J, Demes B, Judex S. Bone shaft bending strength index is unaffected by exercise and unloading in mice. Journal of anatomy. 2015; 226(3):224–8. Epub 2015/02/02. doi: 10.1111/joa.12277 PMID: 25645569.

51. Wallace IJ, Judex S, Demes B. Effects of load-bearing exercise on skeletal structure and mechanics differ between outbred populations of mice. Bone. 2015; 72:1–8. Epub 2014/12/03. doi: 10.1016/j.bone.2014.11.013 PMID: 25460574.

52. Wood LK, Brooks SV. Ten weeks of treadmill running decreases stiffness and increases collagen turnover in tendons of old mice. Journal of orthopaedic research: official publication of the Orthopaedic Research Society. 2015. Epub 2015/02/03. doi: 10.1002/jor.22824 PMID: 25640809.
53. Zheng DM, Bian Z, Furuya N, Oliva Trejo JA, Takeda-Ezaki M, Takahashi K, et al. A treadmill exercise reactivates the signaling of the mammalian target of rapamycin (mTor) in the skeletal muscles of starved mice. Biochemical and biophysical research communications. 2015; 458(1):519–26. Epub 2014/12/09. doi: 10.1016/j.brc.2014.11.118 PMID: 25485704.

54. Zou K, Huntsman HD, Carmen Valero M, Adams J, Skelton J, De Lisio M, et al. Mesenchymal stem cells augment the adaptive response to eccentric exercise. Medicine and science in sports and exercise. 2015; 47(2):315–25. Epub 2014/06/07. doi: 10.1249/mss.0000000000000405 PMID: 24905762.

55. Booth FW, Laye MJ, Spangenberg EE. Gold standards for scientists who are conducting animal-based exercise studies. Journal of applied physiology. 2010; 108(1):219–21. doi: 10.1152/japplphysiol.00125.2009 PMID: 19574508.

56. Ostler JE, Maurya SK, Dials J, Roof SR, Devor ST, Ziolo MT, et al. Effects of insulin resistance on skeletal muscle growth and exercise capacity in type 2 diabetic mouse models. American journal of physiology Endocrinology and metabolism. 2014; 306(6):E592–605. Epub 2014/01/16. doi: 10.1152/ajpendo.00277.2013 PMID: 24425761; PubMed Central PMCID: PMC3948983.

57. Hernandez OM, Szczesna-Cordary D, Knollmann BC, Miller T, Bell M, Zhao J, et al. F1101 and R278C tropinin T mutations that cause familial hypertrophic cardiomyopathy affect muscle contraction in transgenic mice and reconstituted human cardiac fibers. The Journal of biological chemistry. 2005; 280(44):37183–94. Epub 2005/08/24. doi: 10.1074/jbc.M508114200 PMID: 16115869.

58. Calvo JA, Daniels TG, Wang X, Paul A, Lin J, Spiegelman BM, et al. Muscle-specific expression of PPAR-gamma coactivator-1-alpha improves exercise performance and increases peak oxygen uptake. Journal of applied physiology. 2008; 104(4):1304–12. doi: 10.1152/japplphysiol.01321.2007 PMID: 18299076.

59. Fletcher GF, Ades PA, Kligfield P, Arena R, Balady GJ, Bittner VA, et al. Exercise standards for testing and training: a scientific statement from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association; Position paper endorsed by the American College of Sports Medicine. 2003; 15(3):165. doi: 10.1152/physiolgenomics.00033.2003 PMID: 14612588.

60. Doevendans PA, Daemen MJ, de Muinck ED, Smits JF. Cardiovascular phenotyping in mice. Cardiovascular research. 1998; 39(1):34–49. PMID: 9764188.

61. Wessels A, Sedmera D. Developmental anatomy of the heart: a tale of mice and man. Physiological genomics. 2003; 15(3):165–76. doi: 10.1152/physiogenomics.00033.2003 PMID: 14612588.

62. Pollock ML, Franklin BA, Balady GJ, Chaitman BL, Fleg JL, Fletcher B, et al. AHA Science Advisory. Resistance exercise in individuals with and without cardiovascular disease: benefits, rationale, safety, and prescription: An advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association; Position paper endorsed by the American College of Sports Medicine. 2003; 128(8):873–904. doi: 10.1161/CIR.0b013e318265b44 PMID: 12877260.

63. Wisloff U, Helgerud J, Kemi OJ. Intensity-controlled treadmill running in rats: VO(2 max) and cardiac hypertrophy. American journal of physiology Heart and circulatory physiology. 2001; 280(44):H1301–9. Epub 2000/02/23. PMID: 11179077.

64. Henderson KK, Wagner H, Favret F, Britton SL, Koch LG, Wagner PD, et al. Determinants of maximal O(2) uptake in rats selectively bred for endurance running capacity. Journal of applied physiology. 2002; 93(4):1265–74. doi: 10.1152/japplphysiol.00089.2001 PMID: 12235024.

65. Kemi OJ, Loennechen JP, Wisloff U, Ellingsen O. Intensity-controlled treadmill running in mice: cardiac and skeletal muscle hypertrophy. Journal of applied physiology. 2002; 93(4):1301–9. doi: 10.1152/japplphysiol.00231.2002 PMID: 12235029.

66. Fueger PT, Shearer J, Krueger TM, Posey KA, Bracy DP, Heikkinen S, et al. Hexokinase II protein content is augmented the adaptive response to eccentric exercise. Medicine and science in sports and exercise. 2015; 47(2):533–41. doi: 10.1249/mss.0000000000000403 PMID: 15878951; PubMed Central PMCID: PMC1464755.

67. Rezende EL, Garland T Jr, Chappell MA, Malisch JL, Gomes FR. Maximum aerobic performance in lines of Mus selected for high wheel-running activity: effects of selection, oxygen availability and the mini-muscle phenotype. The Journal of experimental biology. 2006; 209(1):115–27. doi: 10.1242/jeb.01883 PMID: 16354783.

68. Ericsson M, Andersson KB, Amundsen BH, Torp SH, Sjaastad I, Christensen G, et al. High-intensity exercise training in mice with cardiomyocyte-specific disruption of Serca2. Journal of applied physiology. 2010; 108(5):1311–20. doi: 10.1152/japplphysiol.01133.2009 PMID: 20167673.

69. Rocco AB, Levalley JC, Eldridge JA, Marsh SA, Rodgers BD. A novel protocol for assessing exercise performance and dystrophophysiology in the mdx mouse. Muscle & nerve. 2014; 50(4):541–8. doi: 10.1002/mus.24184 PMID: 24449511.

70. Wasserman K. The anaerobic threshold measurement in exercise testing. Clinics in chest medicine. 1984; 5(1):77–88. PMID: 6723245.

71. Brooks GA, Mercier J. Balance of carbohydrate and lipid utilization during exercise: the "crossover" concept. Journal of applied physiology. 1994; 76(6):2253–61. Epub 1994/06/01. PMID: 7928844.

72. Wasserman K. Lactate and related acid base and blood gas changes during constant load and graded exercise. Canadian Medical Association journal. 1967; 96(12):775–83. PMID: 6020874; PubMed Central PMCID: PMC1938113.
73. Myers J. Essentials of cardiopulmonary exercise testing. Champaign, IL: Human Kinetics; 1996. xiii, 177 p.
74. Platt C, Houstis N, Rosenzweig A. Using Exercise to Measure and Modify Cardiac Function. Cell metabolism. 2015; 21(2):227–36. doi: 10.1016/j.cmet.2015.01.014 PMID: 25651177; PubMed Central PMCID: PMC4317572.
75. Kalyanasundaram A, Viatchenko-Karpinski S, Bellevych AE, Lacombe VA, Hwang HS, Knollmann BC, et al. Functional consequences of stably expressing a mutant calsequestrin (CASQ2D307H) in the CASQ2 null background. American journal of physiology Heart and circulatory physiology. 2012; 302(1):H253–61. doi: 10.1152/ajpheart.00738.2011 PMID: 21984545; PubMed Central PMCID: PMC3354241.
76. Stolen TO, Hoydal MA, Kemi OJ, Catalucci D, Ceci M, Aasum E, et al. Interval training normalizes cardiomyocyte function, diastolic Ca2+ control, and SR Ca2+ release synchronicity in a mouse model of diabetic cardiomyopathy. Circulation research. 2009; 105(6):527–36. Epub 2009/08/15. doi: 10.1161/CIRCRESAHA.109.199810 PMID: 19679837.
77. Ferreira JC, Rolim NP, Bartholomeu JB, Gobatto CA, Kokubun E, Brum PC. Maximal lactate steady state in running mice: effect of exercise training. Clinical and experimental pharmacology & physiology. 2007; 34(8):760–5. doi: 10.1111/j.1440-1681.2007.04635.x PMID: 17600553.
78. Lund J, Hafstad AD, Boardman NT, Rossvoll L, Rolim NP, Ahmed MS, et al. Exercise training promotes cardioprotection through oxygen-consuming action in high-fat-fed mice. American journal of physiology Heart and circulatory physiology. 2015; 308(8):H823–9. doi: 110.1152/ajpheart.00734.2014 PMID: 25637547.
79. Han Y, Oshida Y, Li L, Koshinaka K, Fuku N, Yamanouchi K, et al. Effect of voluntary wheel-running on insulin sensitivity and responsiveness in high-fat-fed rats. Endocrine journal. 2001; 48(5):551–5. PMID: 11789559.
80. Podolin DA, Wei Y, Pagliassotti MJ. Effects of a high-fat diet and voluntary wheel running on gluconeogenesis and lipolysis in rats. Journal of applied physiology. 1999; 86(4):1374–80. PMID: 10194225.
81. Rezende EL, Chappell MA, Gomes FR, Malisch JL, Garland T Jr. Maximal metabolic rates during voluntary exercise, forced exercise, and cold exposure in house mice selectively bred for high wheel-running. The Journal of experimental biology. 2005; 208(Pt 12):2447–58. doi: 10.1242/jeb.01631 PMID: 15939783.
82. Rezende EL, Gomes FR, Malisch JL, Chappell MA, Garland T Jr. Maximal oxygen consumption in relation to subordinate traits in lines of house mice selectively bred for high voluntary wheel running. Journal of applied physiology. 2006; 101(2):477–85. doi: 110.1152/japplphysiol.00042.2006 PMID: 16601309.
83. Meek TH, Eisenmann JC, Garland T Jr. Western diet increases wheel running in mice selectively bred for high voluntary wheel running. International journal of obesity. 2010; 34(6):960–9. doi: 10.1038/ijo.2010.25 PMID: 20573117.
84. Bassett DR Jr, Howley ET. Limiting factors for maximum oxygen uptake and determinants of endurance performance. Medicine and science in sports and exercise. 2000; 32(1):70–84. PMID: 10647532.
85. Wasserman K, Mcllroy MB. Detecting the Threshold of Anaerobic Metabolism in Cardiac Patients during Exercise. The American journal of cardiology. 1964; 14:844–52. PMID: 14232808.
86. Glukhov AV, Kalyanasundaram A, Lou Q, Hage LT, Hansen BJ, Bellevych AE, et al. Calsequestrin 2 deletion causes sinoatrial node dysfunction and atrial arrhythmias associated with altered sarcoplasmic reticulum calcium cycling and degenerative fibrosis within the mouse atrial pacemaker complex1. European heart journal. 2015; 36(11):866–97. doi: 10.1093/eurheartj/ehu1452 PMID: 24216388; PubMed Central PMCID: PMC4359358.
87. Lerman I, Harrison BC, Freeman K, Hewett TE, Allen DL, Robbins J, et al. Genetic variability in forced and voluntary endurance exercise performance in seven inbred mouse strains. Journal of applied physiology. 2002; 92(6):2245–55. doi: 10.1152/japplphysiol.01045.2001 PMID: 12015333.
88. Courtney SM, Massett MP. Identification of exercise capacity QTL using association mapping in inbred mice. Physiological genomics. 2012; 44(19):948–55. doi: 10.1152/physiolgenomics.00051.2012 PMID: 22911454; PubMed Central PMCID: PMC3472463.
89. Chalmers RJJ, Johnson RH, Al Badran RH, Williams BO. Metabolic changes during exercise testing of patients with ischaemic heart disease. European journal of applied physiology and occupational physiology. 1976; 35(4):261–9. PMID: 976253.
90. Wasserman K, Whipp BJ, Koyl SN, Beaver WL. Anaerobic threshold and respiratory gas exchange during exercise. J Appl Physiol. 1973; 35(2):236–43. PMID: 4723033.
91. Roston WL, Whipp BJ, Davis JA, Cunningham DA, Effros RM, Wasserman K. Oxygen uptake kinetics and lactate concentration during exercise in humans. The American review of respiratory disease. 1987; 135(5):1080–4. PMID: 3579007.
92. Wasserman K, Van Kessel AL, Burton GG. Interaction of physiological mechanisms during exercise. J Appl Physiol. 1967; 22(1):71–85. PMID: 6017656.
93. Darrow MD. Ordering and understanding the exercise stress test. American family physician. 1999; 59(2):401–10. Epub 1999/02/04. PMID: 990131.
94. Wasserman K, Stringer WW, Casaburi R, Koike A, Cooper CB. Determination of the anaerobic threshold by gas exchange: biochemical considerations, methodology and physiological effects. Zeitschrift fur Kardiologie. 1994; 83 Suppl 3:1–12. PMID: 7941654.

95. Gibbons RJ, Balady GJ, Beasley JW, Bricker JT, Duvernoy WF, Froelicher VF, et al. ACC/AHA Guidelines for Exercise Testing. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). Journal of the American College of Cardiology. 1997; 30(1):260–311. Epub 1997/07/01. PMID: 9207652.

96. Desai KH, Sato R, Schaufele B, Barsh GS, Koblika BK, Bernstein D. Cardiovascular indexes in the mouse at rest and with exercise: new tools to study models of cardiac disease. The American journal of physiology. 1997; 272(2 Pt 2):H1053–61. PMID: 9124413.

97. Caiozzo VJ, Davis JA, Ellis JF, Azus JL, Vandagriff R, Prietto CA, et al. A comparison of gas exchange indices used to detect the anaerobic threshold. Journal of applied physiology: respiratory, environmental and exercise physiology. 1982; 53(5):1184–9. PMID: 7174412.

98. Brooks GA. Mammalian fuel utilization during sustained exercise. Comparative biochemistry and physiology Part B, Biochemistry & molecular biology. 1998; 120(1):89–107. PMID: 9787780.

99. Roberts TJ, Weber JM, Hoppeler H, Weibel ER, Taylor CR. Design of the oxygen and substrate pathways. II. Defining the upper limits of carbohydrate and fat oxidation. The Journal of experimental biology. 1996; 199(Pt 8):1651–8. PMID: 8708572.

100. Wieland OH. The mammalian pyruvate dehydrogenase complex: structure and regulation. Reviews of physiology, biochemistry and pharmacology. 1983; 96:123–70. PMID: 6338572.

101. Putman CT, Jones NL, Lands LC, Bragg TM, Hollidge-Horvat MG, Heigenhauser GJ. Skeletal muscle pyruvate dehydrogenase activity during maximal exercise in humans. The American journal of physiology, 1995; 269(3 Pt 1):E458–68. PMID: 7573423.

102. Krahwinkel W, Ketteler T, Godke J, Wolfertz J, Ulbricht LJ, Krakau I, et al. Dobutamine stress echocardiography. European heart journal. 1997; 18 Suppl D:D9–15. PMID: 9183605.

103. Wiesmann F, Ruff J, Engelhardt S, Hein L, Dieniess C, Leupold A, et al. Dobutamine-stress magnetic resonance microimaging in mice: acute changes of cardiac geometry and function in normal and failing murine hearts. Circulation research. 2001; 88(6):563–9. Epub 2001/04/03. PMID: 11282889.

104. Lujan HL, DiCarlo SE. Cardiac output, at rest and during exercise, before and during myocardial ischemia, reperfusion, and infarction in conscious mice. American journal of physiology Regulatory, integrative and comparative physiology. 2013; 304(4):R286–95. doi: 10.1152/ajpregu.00517.2012 PMID: 23302959; PubMed Central PMCID: PMC35567356.